24.04.2024 16:26:17 - dpa-AFX: *IMMUTEP: PHASE IIB TRIAL SHOWS POSITIVE RESULTS IN FIRST-LINE HNSCC TREATMENT WITH EFTILAGIMOD ALPHA

Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX
Name WKN Börse Kurs Datum/Zeit Diff. Diff. % Geld Brief Erster Schluss
MERCK CO. DL-,01 A0YD8Q Xetra 121,000 08.05.24 15:20:18 +1,800 +1,51% 120,400 121,800 121,000 119,200

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH